A Novel Approach for the Treatment of Hepatocellular Carcinoma Using a Combination of Sorafenib and a Novel Drug Delivery System
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide. Current treatment options are limited, and novel therapeutic strategies are urgently needed. In this study, we investigated the efficacy of a novel drug delivery system (DDS) loaded with sorafenib, a multi-kinase inhibitor, in a preclinical model of HCC. Our results demonstrate that the DDS significantly enhances the antitumor activity of sorafenib, reduces systemic toxicity, and improves overall survival. Mechanistically, the DDS promotes targeted delivery to tumor cells, leading to increased apoptosis and inhibition of angiogenesis. These findings suggest that the combination of sorafenib with this novel DDS represents a promising therapeutic approach for HCC, warranting further clinical investigation.